// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Topographical incidence and survival analysis of gastrointestinal tract cancer in adolescent and young adults compared with older adults in the United States.

Oren Hannun Levine - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Clinical Risk Factors for Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant Recipients (LTRs): Results of an International Cohort Study.

N. Law - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

N/A

N/A

Survival impact of CAPOX versus FOLFOX in the adjuvant treatment of stage III colon cancer.

Jonathan M. Loree - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

mFOLFOX6

Comparing Renal Function Recovery and Long Term Outcomes in Recipients of Standard and Expanded Criteria Donor Kidney Transplants.

S. Sandal - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Complement Activating Anti-HLA Antibodies: Identification of Specific Histo-Mmolecular Phenotype of Rejection for Complement-Targeting Therapy.

C. Lefaucheur - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Interferon Gamma

Long-chain omega-3 fatty acid and fish intake after colon cancer diagnosis and disease-free, recurrence-free, and overall survival in CALGB 89803 (Alliance).

Erin Van Blarigan - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Conversion from Twice Daily to Once Daily Tacrolimus Improves Adherence in Kidney Transplant Recipients.

M. Levine - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Tacrolimus

Cumulative Deficits Frailty Index for Transplant Candidates Predicts Candidacy for Solid Organ Transplantation.

R. Varughese - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

CXCL13 as a New Systemic Biomarker for B-Cell Involvement in Acute Kidney Allograft Rejection.

L. Schiffer - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Other

N/A

N/A

Gemcitabine plus nab-paclitaxel use in metastatic pancreatic cancer: A study of 40 patients.

Ivan Barrera - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Gemcitabine

Death After Kidney Transplantation: Assessment of Pre- and Peri-Transplant Risk Factors and of Time-Varying Risk Factors from the Post-Transplant Course.

I. Scheffner - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

N/A

N/A

Impact of CEA alone or as part of a high intensity surveillance strategy in detecting curative colorectal cancer recurrence: A systematic review and meta-analysis.

Marck Mercado - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Detection of Specific B Cell Memory to the Perlecan LG3 Antigen in the Normal Immune Repertoire.

L. Padet - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Development and Validation of PART (Pharmacotherapy Assessment in Renal Transplant Patients) Criteria to Assess Drug Related Problems in Outpatient Renal Transplant Population.

L. El Raichani - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Differential Effect of Antibody Removal on ABO Blood Group Type Chain Specific Antibodies Over Time.

A. Bentall - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Do Perioperative Blood Transfusions Influence Kidney Transplant Outcomes in the Modern Era?

J. Lineen - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Sequential treatment in patients with metastatic pancreatic neuroendocrine tumors after progression on first-line therapy.

Erica S Tsang - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Donation After Circulatory Death (DCD) Kidneys Are More Likely to Be Discarded than Kidneys from Neurologically Brain Dead Donors (NBD).

J. Gill - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Donor Age Is the Most Important Predictor of Longterm Graft Function in Simultaneous Pancreas-Kidney Transplantation from Donors After Cardiac Death.

J. Chen - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Nephrology

N/A

N/A

Donor Kidney Volume Predicts One and Three Month eGFR in Live Donor Kidney Transplant Recipients.

D. Al-Adra - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved